8.77
0.77 (9.63%)
| Previous Close | 8.00 |
| Open | 7.96 |
| Volume | 1,349,324 |
| Avg. Volume (3M) | 757,549 |
| Market Cap | 675,034,752 |
| Price / Book | 1.28 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2025 - 19 May 2025 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 15.76% |
| Current Ratio (MRQ) | 11.43 |
| Operating Cash Flow (TTM) | -184.68 M |
| Levered Free Cash Flow (TTM) | -112.70 M |
| Return on Assets (TTM) | -26.30% |
| Return on Equity (TTM) | -50.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Replimune Group, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -4.0 |
| Average | 0.00 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.61% |
| % Held by Institutions | 101.93% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sofinnova Investments, Inc. | 31 Dec 2024 | 3,149,522 |
| Omega Fund Management, Llc | 31 Dec 2024 | 1,975,203 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (HC Wainwright & Co., 151.00%) | Buy |
| Median | 20.00 (128.18%) | |
| Low | 18.00 (JP Morgan, 105.36%) | Buy |
| Average | 20.00 (128.18%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 13.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 26 Feb 2025 | 18.00 (105.36%) | Buy | 13.24 |
| HC Wainwright & Co. | 13 Feb 2025 | 22.00 (151.00%) | Buy | 14.29 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Apr 2025 | Announcement | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Mar 2025 | Announcement | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Feb 2025 | Announcement | Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update |
| 07 Feb 2025 | Announcement | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |